


REMARKS

Applicants have attached an abstract on a separate sheet of paper as required by U.S. practice. Applicants have amended the specification for purposes of adding the priority information. Claims 3, 4, and 6 - 14 have been amended to remove multiple dependencies. Claims 15, 16, and 17 have been added. Support for claim 15 is found in the specification at page 5. Support for claims 16 and 17 is found in the specification at page 4. Claims 1 – 17 are pending in the application. No new matter has been added. It is respectfully submitted that the present application is in condition for examination. An early consideration and notice of allowance are earnestly solicited.

Respectfully submitted,

Date: May 2, 2005



Karen L. Prus
Attorney of Record, Reg. No 39,337

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: 919-483-2192
Fax: 919-483-7988

ABSTRACT

A pharmaceutical composition comprising 3'-azido-3'-deoxythymidine and (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one suitable for once daily administration